Ashburton Jersey Ltd Has $9.86 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Sep 13th, 2023

Ashburton Jersey Ltd lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 40.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 63,582 shares of the company’s stock after selling 42,332 shares during the period. Johnson & Johnson makes up 4.6% of Ashburton Jersey Ltd’s holdings, making the stock its 11th biggest holding. Ashburton Jersey Ltd’s holdings in Johnson & Johnson were worth $9,855,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GW&K Investment Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP boosted its holdings in shares of Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares in the last quarter. Atlantic Private Wealth LLC bought a new position in shares of Johnson & Johnson in the 1st quarter valued at $32,000. Ruedi Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $42,000. Finally, Kepos Capital LP bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $45,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.6 %

Johnson & Johnson stock opened at $163.64 on Wednesday. The firm has a market cap of $425.30 billion, a price-to-earnings ratio of 33.13, a PEG ratio of 3.47 and a beta of 0.54. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The firm has a 50 day moving average price of $166.10 and a two-hundred day moving average price of $161.64.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the firm earned $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 10.03 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 96.36%.

Analyst Ratings Changes

Several research analysts have commented on JNJ shares. StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 8th. TheStreet raised shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Raymond James decreased their target price on shares of Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 5th. Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price target for the company. Finally, Barclays reduced their price objective on Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating on the stock in a research report on Friday, September 8th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $170.65.

Read Our Latest Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.